The confidence of the French drug maker Sanofi has increased during this summer as the company gets ready to begin clinical trials.
The chief executive if the company said in an interview to Reuters that two of the more than 150 potential vaccines against Covid-19 being developed across the world is being prepared by the company
One of the vaccine candidates of the company is set to be made on the back of an existing platform that currently manufactures vaccines against flu. This vaccine will increase its efficacy with the use of an adjuvant made by Britain’s GlaxoSmithKline (GSK).
The other vaccine candidate that the company is working on relies on a different technology known as mRNA and is being developed together with the United States based company Translate Bio.
“The early data is saying that we’re on the right track and that we have a vaccine,” Paul Hudson said in an interview on Friday, referring to the vaccine being developed with GSK.
The company is set to start clinical trials of the vaccine next month.
Human trials are being carried out for about 30 experimental coronavirus vaccines. The chances of the vaccines being developed by Sanofi of having an efficacy of more than 70% is a reality and will be higher than that of the rivals because of the experience of the company in making vaccines, Hudson had said in June.
“Our confidence has increased. We have work to do like everybody on manufacturing in large volumes. But we will have one, maybe two vaccines next year,” Hudson said.
An immune response in non-human studies has been induced by the mRNA vaccine, Translate Bio said on Tuesday and the company expects to begin human trials in November.
After having confirmed deals with the United States and Britain for the vaccine-plus-adjuvant, Sanofi is now in advanced talks with the European Union for providing it with up to 300 million doses.
However, according to statements made by EU officials earlier this week, only partial protection to vaccine makers against the legal risks from side-effects of the possible shots is being provided by the EU. That is hampering potential deals with vaccine makers unlike in the US.
“I think with the level of protection, we have reached an ‘agreed level’. And I think that has allowed us to go forward and sign. But I am aware there are different positions on how strong that is,” Hudson said.
There is a greater possibility than usual of vaccines resulting in unexpected consequences or not be effective because of the record speed with at which vaccines are being developed during the pandemic. And one of the features of drug makers’ talks with governments keen to secure vaccine shots in advance is the financial coverage of these liabilities.
Except one vaccine that has been authorized in Russia before large-scale trials, there is currently no approved coronavirus vaccine.
(Sourc:www.reuters.com)
The chief executive if the company said in an interview to Reuters that two of the more than 150 potential vaccines against Covid-19 being developed across the world is being prepared by the company
One of the vaccine candidates of the company is set to be made on the back of an existing platform that currently manufactures vaccines against flu. This vaccine will increase its efficacy with the use of an adjuvant made by Britain’s GlaxoSmithKline (GSK).
The other vaccine candidate that the company is working on relies on a different technology known as mRNA and is being developed together with the United States based company Translate Bio.
“The early data is saying that we’re on the right track and that we have a vaccine,” Paul Hudson said in an interview on Friday, referring to the vaccine being developed with GSK.
The company is set to start clinical trials of the vaccine next month.
Human trials are being carried out for about 30 experimental coronavirus vaccines. The chances of the vaccines being developed by Sanofi of having an efficacy of more than 70% is a reality and will be higher than that of the rivals because of the experience of the company in making vaccines, Hudson had said in June.
“Our confidence has increased. We have work to do like everybody on manufacturing in large volumes. But we will have one, maybe two vaccines next year,” Hudson said.
An immune response in non-human studies has been induced by the mRNA vaccine, Translate Bio said on Tuesday and the company expects to begin human trials in November.
After having confirmed deals with the United States and Britain for the vaccine-plus-adjuvant, Sanofi is now in advanced talks with the European Union for providing it with up to 300 million doses.
However, according to statements made by EU officials earlier this week, only partial protection to vaccine makers against the legal risks from side-effects of the possible shots is being provided by the EU. That is hampering potential deals with vaccine makers unlike in the US.
“I think with the level of protection, we have reached an ‘agreed level’. And I think that has allowed us to go forward and sign. But I am aware there are different positions on how strong that is,” Hudson said.
There is a greater possibility than usual of vaccines resulting in unexpected consequences or not be effective because of the record speed with at which vaccines are being developed during the pandemic. And one of the features of drug makers’ talks with governments keen to secure vaccine shots in advance is the financial coverage of these liabilities.
Except one vaccine that has been authorized in Russia before large-scale trials, there is currently no approved coronavirus vaccine.
(Sourc:www.reuters.com)
Homepage
Send to a friend
Printable version
Share
